On June 29, the Drug Enforcement Administration will convene a formal hearing to evaluate whether marijuana should be moved out of Schedule I of the Controlled Substances Act - the federal government's most restrictive drug classification, one it currently shares with heroin and LSD. The proceedings must conclude by July 15. For licensed cannabis operators, multi-state operators, compliance teams, and the broader ecosystem of dispensary technology vendors and payment providers that serves them, the outcome carries consequences that run well beyond symbolism.
The hearing follows an April Department of Justice order that moved FDA-approved marijuana products and state-licensed medical cannabis into Schedule III - a less restrictive category that permits expanded medical research. That move itself was a direct response to a 2023 Department of Health and Human Services recommendation that the existing classification was scientifically indefensible. For operators running Metrc-compliant POS for Massachusetts and other state-licensed markets, federal rescheduling would not immediately change the daily mechanics of seed-to-sale tracking, compliance reporting, or excise tax remittance - but it would alter the legal architecture that shapes banking access, 280E tax exposure, and wholesale supply chain rules in ways that ripple directly into store economics.
This is a strikingly late debate to be having. Forty states, the District of Columbia, and several U.S. territories have legalized medical cannabis. Twenty-four states allow adult-use sales. More than 6 million patients are registered in state medical programs. Tens of millions of Americans purchase cannabis legally at licensed dispensaries today, paying state excise taxes, receiving products tested against COA-backed lab standards, and buying from retailers who risk license revocation for selling to minors. Yet the federal framework governing research, banking, and taxation has not kept pace with this reality for more than five decades.
A Placeholder That Became Permanent Policy
The origin of marijuana's Schedule I status was never scientific consensus. When Congress passed the Controlled Substances Act in 1970, cannabis was placed in Schedule I explicitly as a provisional measure, pending review by a presidential commission. The Shafer Commission - composed largely of President Nixon's own appointees - concluded in 1972 that marijuana did not meet the criteria for Schedule I and recommended decriminalizing personal possession. Nixon rejected the recommendation and deepened federal enforcement instead. The provisional classification hardened into permanent policy by inaction. Since 1965, an estimated 29 million Americans have been arrested on marijuana charges, roughly 90 percent for possession alone.
The most consequential damage, however, has not been to consumers who gained access through state legalization. It has been to the research enterprise. Schedule I carries the most restrictive regulatory barriers under federal law: heightened DEA registration requirements, limited sourcing options, and protocol approvals that can delay or deter studies for years. Even DEA-registered researchers have at times been barred from using certain National Institutes of Health grants to purchase cannabis. The government-approved supply of cannabis available for research has not reflected what patients and adult-use consumers actually purchase at dispensaries - which means the evidence base guiding physicians, regulators, and policymakers has been built on an incomplete picture.
What the Science Currently Shows - and What It Doesn't
The scientific case for medical use has only strengthened despite these constraints. The FDA has approved one cannabis-derived drug - Epidiolex, for severe pediatric epilepsy - and three cannabis-related synthetic compounds for chemotherapy-induced nausea and AIDS-associated wasting. A 2024 systematic evidence map reviewing 194 studies found that the majority of treatment effects across 71 distinct health outcomes were positive or potentially positive, with the strongest evidence concentrated in chronic pain, nausea, and spasticity. The Department of Health and Human Services cited this body of evidence when it recommended rescheduling in 2023.
At the same time, the risks are real and underresearched. A multisite study published in The Lancet Psychiatry, drawing on data from 901 patients with first-episode psychosis across 11 European sites, found that daily cannabis use was associated with more than three times the odds of a psychotic disorder - rising to nearly five times for users of high-potency products containing over 10 percent THC. A 2022 systematic review of 20 studies covering nearly 120,000 cannabis users confirmed that higher-potency products are associated with elevated risk of both psychosis and cannabis use disorder. A 2025 review in the American Journal of Psychiatry concluded that frequent cannabis use, particularly high-THC products, can disrupt adolescent brain development. Average THC concentrations in commercially available products have risen by roughly 0.29 percent per year from 1970 to 2017. Today's dispensary SKUs bear little resemblance to the products evaluated in the early 1970s.
Here's the catch: Schedule I classification has not prevented any of this. It has mainly ensured that policymakers, physicians, and consumers are making decisions with less reliable evidence than they otherwise would. The same regulatory structure designed to protect public health has blocked the research needed to define what that protection should actually look like.
What Rescheduling Would - and Would Not - Change for Operators
For licensed cannabis businesses, the practical implications depend heavily on what rescheduling ultimately produces in downstream policy. Moving marijuana to Schedule III would not, on its own, resolve the banking access problems that force many dispensaries into cash-heavy operations, complicate armored transport logistics, and leave retailers underserved by mainstream financial institutions. It would not immediately eliminate the 280E tax provision that prevents cannabis businesses from deducting ordinary business expenses - though the legal argument for 280E's applicability weakens considerably if cannabis is no longer classified as a Schedule I or II substance, and operators and their tax counsel are watching that question closely.
What rescheduling would change is the federal research environment. Expanded research access means that the evidence base supporting medical cannabis programs would grow more robust, which matters for state regulators writing product safety rules, for lab testing standards applied to dispensary inventory, and for the physician-certification infrastructure that underpins medical programs in states where adult-use remains off the table. It also matters for the potency conversation. Without adequate clinical research, regulators have been setting THC concentration limits and labeling standards largely on precautionary grounds rather than dose-response data. Better science produces better compliance frameworks - and that is ultimately a better operating environment for licensed retailers.
Public opinion is not the obstacle here. According to a Pew Research Center survey conducted in January 2026, roughly nine in 10 American adults support marijuana legalization in some form. A 2025 Gallup poll found 64 percent support outright legalization - more than double the level recorded in 2000. The political will has been building for years. What the June 29 hearing represents is the federal bureaucracy finally catching up, however slowly, to a market that has been operating at scale for over a decade. Licensed operators have built compliance programs, invested in tracking infrastructure, and paid state excise taxes in full - all while managing the distortions created by a federal classification that the government's own health agencies now say was wrong. That is not a sustainable foundation for a regulated industry.
